Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected in the Fourth Quarter of 2025 Signed AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 Beyond MASH $17.6 Million in Cash at End of Second Quarter is Expected to Fund the Company Into 2026 CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate strategic update.

Extension is Designed to Assess Early Efficacy and Patient Safety and Tolerability with Longer-Term Exposure to DA-1726 and Further Explore Non-Titrated Maximum Tolerated Dose Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has extended to 8 weeks from 4 weeks, the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, and has administered a fifth weekly dose to the first patient. DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-lik

Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential of MetaVia's Oral GPR119 Agonist CAMBRIDGE, Mass., Aug. 4, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven drug discovery company, to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia's novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist. T

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025. "T

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of pre-clinical data on DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, demonstrating  additive hepatoprotective effects in combination with Efruxifermin, a fibroblast growth factor 21 (FGF21) analogue, in a metabolic dysfunction-associated steatohepatitis (MASH) mouse model. The data will be presented in a poster session, tomorrow, at the American Diabetes Association's 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago,

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer will present a company overview live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, taking place June 11-12, 2025. DATE: Wednesday June 12, 2025 TIME: 1:00 – 1:30 pm ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12, 13, and 16 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on t

CAMBRIDGE, Mass., June 4, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting pre-clinical data on DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has been accepted for a poster presentation at the American Diabetes Association's 85th Scientific Sessions, taking place June 20-23, 2025 at the McCormick Place Convention Center in Chicago, Illinois. Title: Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combinatio

MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

SCHEDULE 13G/A - MetaVia Inc. (0001638287) (Subject)

8-K - MetaVia Inc. (0001638287) (Filer)

10-Q - MetaVia Inc. (0001638287) (Filer)

8-K - MetaVia Inc. (0001638287) (Filer)

8-K - MetaVia Inc. (0001638287) (Filer)

8-K - MetaVia Inc. (0001638287) (Filer)

EFFECT - MetaVia Inc. (0001638287) (Filer)

424B3 - MetaVia Inc. (0001638287) (Filer)

8-K - MetaVia Inc. (0001638287) (Filer)

S-3 - MetaVia Inc. (0001638287) (Filer)

H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)